Showing results (381-390 of 458) with videos related to

Sort By:
Pageof 46
The Lancet. Oncology|November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trialChristopher J Logothetis, Ethan Basch, Arturo Molina, et al.
The Lancet. Oncology|March 7, 2015
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trialDaniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, et al.
The Oncologist|August 6, 2021
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic DiseaseRisa L Wong, Lorin A Ferris, Olivia A Do, et al.
The Lancet. Oncology|September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 studyKarim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
The New England Journal of Medicine|February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2013
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohortRoberto Iacovelli, Giacomo Cartenì, Cora N Sternberg, et al.
Frontiers in Oncology|December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC DatabaseGabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upY Fradet, J Bellmunt, D J Vaughn, et al.
Cancers|July 29, 2025
Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100Thomas Powles, Srikala S Sridhar, Joaquim Bellmunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial CancerYohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.
Pageof 46